Dr. Susan Love Research Foundation is committed to performing and advancing research that will lead to the discovery of what causes cancer to develop in the human breast. As part of this effort, the Foundation hosted the 8th International Symposium on the Breast in Santa Monica, Calif., Feb. 19 to Feb. 21, 2015. More than 120 forward-thinking clinical researchers, epidemiologists, pathologists, basic scientists, translational investigators, and breast cancer advocates from six countries attended this year’s conference, “Using Next Generation Science to Understand the Normal Breast and the Development of Cancer.” The highlights from this year’s symposium are summarized in this report.
Breast Cancer Normal Breast Tissue Nipple Aspirate Fluid Ductal Lavage Mammary Ductoscopy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The formal proceedings were followed by presentations from the 14 teams that were formed during the Symposium to compete for pilot grants. Additionally, public presentations were done by Dr. Susan love and four other participants of the consortium. Commenting from the audience, Judith Salerno, M.D., president and CEO of Susan G. Komen, said, “I spent many years at the NIH funding safe science. It was energizing to be here and to see this research. I’m glad we could support it.”
Consortium Grant Awards
At the end of the Symposium, Dr. Susan Love Research Foundation awarded a total of $50,000 in grants funded by Susan G. Komen to support multidisciplinary consortia formed at the Symposium. Additionally, Atossa Genetics also sponsored research from this consortia. Grant recipients and their titles are listed in appendix A.
Compliance with ethical standards
Conflicts of Interest
Authors AG and SL have no conflicts of interest to report with this manuscript.
Karim SA et al (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. J Pathol 230(4):430–440CrossRefPubMedGoogle Scholar
Degnim AC et al (2012) Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat 133(1):169–177PubMedCentralCrossRefPubMedGoogle Scholar
Inman JL et al (2015) Mammary gland development: cell fate specification, stem cells and the microenvironment. Development 142(6):1028–1042CrossRefPubMedGoogle Scholar
Roll JD et al (2013) Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol 95(3):276–287CrossRefPubMedGoogle Scholar
Rajan SS et al (2014) Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. J Control Release 194:301–309CrossRefGoogle Scholar
Teo WW, Sukumar S (2014) Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment. Breast Cancer Res 16(2):306PubMedCentralCrossRefPubMedGoogle Scholar
Cheng Q et al (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14(2):R62PubMedCentralCrossRefPubMedGoogle Scholar
Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM (2015) Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma. Cancer Immunol Res 3:1165CrossRefPubMedGoogle Scholar